Form 4: Perceptive Advisors Sells Shares of Acrivon Therapeutics (ACRV)
SEC Form 4
Perceptive Advisors LLC, along with related entities, sold shares of Acrivon Therapeutics (ACRV) between April 25 and April 29, 2025.
Summary
- Perceptive Advisors LLC, Perceptive Life Sciences Master Fund Ltd., and Joseph Edelman reported the sale of Acrivon Therapeutics (ACRV) shares.
- The transactions occurred between April 25, 2025, and April 29, 2025.
- On April 25, 2025, 1,054,669 shares were sold at an average price of $1.95.
- On April 28, 2025, 215,283 shares were sold at an average price of $1.56.
- On April 29, 2025, 250,000 shares were sold at an average price of $1.41.
- Following these transactions, Perceptive Life Sciences Master Fund Ltd. indirectly holds 3,840,906 shares.
Sentiment
Score: 3
Explanation: The sentiment is negative due to the sale of shares by a major holder, which could indicate a lack of confidence or a change in investment strategy. This can create selling pressure on the stock.
Negatives
- Perceptive Advisors LLC reduced its holdings in Acrivon Therapeutics (ACRV) through a series of sales.
Risks
- Continued selling pressure from major shareholders like Perceptive Advisors could negatively impact ACRV's stock price.
Industry Context
Sales by major shareholders are common and can reflect portfolio adjustments or changes in investment strategy. It's important to consider the overall context of the company's performance and industry trends when interpreting these transactions.
Stakeholder Impact
- Shareholders may experience downward pressure on the stock price due to the sale of shares by a major holder.
- The company may need to address investor concerns related to the reasons for the share sale.
Key Dates
| Date | Description |
|---|---|
| 04/25/2025 | Sale of 1,054,669 shares at an average price of $1.95 |
| 04/28/2025 | Sale of 215,283 shares at an average price of $1.56 |
| 04/29/2025 | Sale of 250,000 shares at an average price of $1.41 |
| 04/29/2025 | Filing date of the Form 4 |
Keywords
Acrivon Therapeutics, ACRV, Perceptive Advisors, share sale, beneficial ownership, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.